About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

RECRUITINGNCT06673043

Anifrolumab Real-world Treatment Outcomes in Systemic Lupus Erythematosus

The Polish multicentre observational (non-interventional) study aiming to collect data on the characteristic of patients with systemic lupus erythematosus and clinical outcomes of anifrolumab administ...

Lead sponsor: AstraZeneca•11 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Contacts

AstraZeneca Clinical Study Information Center

CONTACT

1-877-240-9479 information.center@astrazeneca.com

Sponsors

Lead Sponsor

AstraZeneca

This is multicenter, observational, cohort study designed to collect longitudinal data on the management and clinical outcomes of patients with SLE that received anifrolumab in the scope of routine clinical practice within the frames of National Drug Program (NDP) for up to 30 months (\~ 6 months baseline and \~24 months follow-up date).

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. Adult (aged ≥18 years old) patients with SLE who received anifrolumab treatment in the frames of NDP in Poland.
•2. Patients willing to participate in the study and signed Informed Consent Form (ICF).

Exclusion Criteria

•1. Those who participated in anifrolumab clinical trial in the past, and/or those who participated/plans to participate in clinical trial on/after the date of first anifrolumab infusion through NDP.
•2. Cognitive incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.

Related studies

Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.

NCT07330245 · Lupus Erythematosus, Systemic

RECRUITINGPhase 2

A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

NCT07015983 · Lupus Erythematosus, Systemic, Lupus Nephritis

RECRUITINGPhase 3

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

NCT07438496 · Lupus Erythematosus, Systemic

RECRUITINGPhase 3

A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus

NCT05648500 · Lupus Erythematosus, Systemic

RECRUITINGPhase 1

Vunakizumab for the Treatment of Mild to Moderate Systemic Lupus Erythematosus

NCT06881290 · Lupus Erythematosus, Systemic

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: March 12, 2026Terms

Trial snapshot

StatusRECRUITING

Phase—

Enrollment100

Start dateFeb 2025

Last updatedMar 12, 2026

Condition

Lupus Erythematosus, Systemic

Locations shown

Research Site

Bydgoszcz

Research Site

Bytom

Research Site

Gdansk

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 12, 2026Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions